Zynerba Pharmaceuticals Inc (ZYNE) gains 3.22% for July 21

Equities Staff  |

Zynerba Pharmaceuticals Inc (NASDAQ: ZYNE) shares gained 3.22%, or $0.15 per share, to close Wednesday at $4.81. After opening the day at $4.65, shares of Zynerba fluctuated between $4.84 and $4.63. 349,513 shares traded hands a decrease from their 30 day average of 709,799. Wednesday's activity brought Zynerba’s market cap to $198,419,893.

Zynerba is headquartered in Devon, Pennsylvania..

About Zynerba Pharmaceuticals Inc

Zynerba Pharmaceuticals is the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. Zynerba Pharmaceuticals is committed to improving the lives of patients and their families living with severe, chronic health conditions including Fragile X syndrome, autism spectrum disorder, 22q11.2 deletion syndrome, and a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies.

Visit Zynerba Pharmaceuticals Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Zynerba Pharmaceuticals Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Zynerba Pharmaceuticals Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content